Humedix

휴메딕스 · 200670

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$214.8M (₩296.5B)

Overview

Humedix makes hyaluronic acid-based dermal fillers, injectable gels used to smooth wrinkles and restore facial volume, as well as injections that treat joint pain from arthritis.

Its products reach clinics, hospitals, and cosmetic practitioners in both the domestic South Korean market and internationally. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company operates two distinct divisions: an aesthetics unit covering fillers, a botulinum toxin product, cosmetics, and skin-care devices, and a contract manufacturing unit that produces prescription drugs, eye drops, and active pharmaceutical ingredients.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$123.2M

▲ +5.1% YoY

Operating profit · FY2025

US$30.7M

▼ −1.9% YoY

Net income · FY2025

US$37.5M

▲ +31.9% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$110.3M(₩152.3B)	US$117.3M(₩161.9B)	US$123.2M(₩170.1B)
Operating profit	US$27M(₩37.3B)	US$31.3M(₩43.1B)	US$30.7M(₩42.3B)
Net income	US$18M(₩24.8B)	US$28.4M(₩39.3B)	US$37.5M(₩51.8B)

Revenue

FY2023US$110.3M
FY2024US$117.3M
FY2025US$123.2M

Operating profit

FY2023US$27M
FY2024US$31.3M
FY2025US$30.7M

Net income

FY2023US$18M
FY2024US$28.4M
FY2025US$37.5M

Key ratios (FY2025)

ROE

17.3%

Debt/Eq

8.0%

Op. margin

24.9%

Net margin

30.4%

Rev. YoY

▲ +5.1%

Why it matters

The company's contract manufacturing division produces finished pharmaceuticals and raw active ingredients, meaning it serves both its own branded product lines and third-party pharmaceutical clients.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?